Journal of Experimental & Clinical Cancer Research,
Год журнала:
2024,
Номер
43(1)
Опубликована: Дек. 23, 2024
Abstract
Ductal
carcinoma
in
situ
(DCIS)
is
a
noninvasive
breast
disease
that
variably
progresses
to
invasive
cancer
(IBC).
Given
the
unpredictability
of
this
progression,
most
DCIS
patients
are
aggressively
managed
similar
IBC
patients.
Undoubtedly,
treatment
paradigm
places
many
at
risk
overtreatment
and
its
significant
consequences.
Historically,
prognostic
modeling
has
included
assessment
clinicopathological
features
genomic
markers.
Although
these
provide
valuable
insights
into
tumor
biology,
they
remain
insufficient
predict
which
will
progress
IBC.
Contemporary
work
begun
focus
on
microenvironment
surrounding
ductal
cells
for
molecular
patterns
might
progression.
In
review,
extracellular
alterations
occurring
with
malignant
transformation
from
detailed.
Not
only
do
changes
collagen
abundance,
organization,
localization
mediate
transition
IBC,
but
also
discrete
post-translational
regulation
fibers
understood
promote
invasion.
Other
matrix
proteins,
such
as
metalloproteases,
decorin,
tenascin
C,
have
been
characterized
their
role
further
demonstrate
value
matrix.
Importantly,
proteins
influence
immune
fibroblasts
toward
pro-tumorigenic
phenotypes.
Thus,
progressive
play
key
invasion
promise
development.
Experimental Hematology and Oncology,
Год журнала:
2024,
Номер
13(1)
Опубликована: Авг. 5, 2024
Abstract
Chimeric
antigen
receptor
macrophage
(CAR-MΦ)
represents
a
significant
advancement
in
immunotherapy,
especially
for
treating
solid
tumors
where
traditional
CAR-T
therapies
face
limitations.
CAR-MΦ
offers
promising
approach
to
target
and
eradicate
tumor
cells
by
utilizing
macrophages’
phagocytic
antigen-presenting
abilities.
However,
challenges
such
as
the
complex
microenvironment
(TME),
variability
expression,
immune
suppression
limit
their
efficacy.
This
review
addresses
these
issues,
exploring
mechanisms
of
action,
optimal
construct
designs,
interactions
within
TME.
It
also
delves
into
ex
vivo
manufacturing
CAR-MΦ,
discussing
autologous
allogeneic
sources
importance
stringent
quality
control.
The
potential
synergies
integrating
with
existing
cancer
like
checkpoint
inhibitors
conventional
chemotherapeutics
are
examined
highlight
possible
enhanced
treatment
outcomes.
Furthermore,
regulatory
pathways
scrutinized
alongside
established
protocols
cells,
identifying
unique
considerations
essential
clinical
trials
market
approval.
Proposed
safety
monitoring
frameworks
aim
manage
adverse
events,
cytokine
release
syndrome,
crucial
patient
safety.
Consolidating
current
research
insights,
this
seeks
refine
therapeutic
applications,
overcome
barriers,
suggest
future
directions
transition
from
experimental
platforms
standard
care
options.
Journal of Advanced Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
After
significant
advancements
in
tumor
treatment,
personalized
cell
therapy
based
on
chimeric
antigen
receptors
(CAR)
holds
promise
for
transforming
the
management
of
various
diseases.
CAR-T
therapy,
first
approved
CAR
product,
has
demonstrated
therapeutic
potential
treating
infectious
diseases,
autoimmune
disorders,
and
fibrosis.
CAR-macrophages
(CAR-Ms)
are
emerging
as
a
promising
approach
immune
particularly
solid
highlighting
feasibility
using
macrophages
to
eliminate
pathogens
abnormal
cells.
Cancer Letters,
Год журнала:
2024,
Номер
unknown, С. 217350 - 217350
Опубликована: Ноя. 1, 2024
Pancreatic
cancer
remains
one
of
the
most
challenging
malignancies
to
treat
due
its
late-stage
diagnosis,
aggressive
progression,
and
high
resistance
existing
therapies.
This
review
examines
latest
advancements
in
early
detection,
therapeutic
strategies,
with
a
focus
on
emerging
biomarkers,
tumor
microenvironment
(TME)
modulation,
integration
artificial
intelligence
(AI)
data
analysis.
We
highlight
promising
including
microRNAs
(miRNAs)
circulating
DNA
(ctDNA),
that
offer
enhanced
sensitivity
specificity
for
early-stage
diagnosis
when
combined
multi-omics
panels.
A
detailed
analysis
TME
reveals
how
components
such
as
cancer-associated
fibroblasts
(CAFs),
immune
cells,
extracellular
matrix
(ECM)
contribute
therapy
by
creating
immunosuppressive
barriers.
also
discuss
interventions
target
these
components,
aiming
improve
drug
delivery
overcome
evasion.
Furthermore,
AI-driven
analyses
are
explored
their
potential
interpret
complex
data,
enabling
personalized
treatment
strategies
real-time
monitoring
response.
conclude
identifying
key
areas
future
research,
clinical
validation
regulatory
frameworks
AI
applications,
equitable
access
innovative
comprehensive
approach
underscores
need
integrated,
outcomes
pancreatic
cancer.
Cellular Immunology,
Год журнала:
2025,
Номер
409-410, С. 104932 - 104932
Опубликована: Фев. 17, 2025
CD163-expressing
macrophages
are
abundant
in
ovarian
cancer
where
they
accelerate
tumor
growth
and
metastasis.
CD47
blockade
is
a
novel
immunotherapy
aiming
to
activate
macrophage
phagocytosis
of
cells,
but
it
currently
unknown
if
the
tumor-associated
expressing
CD163
respond
poorly
blockade.
Human
monocyte-derived
were
exposed
tumor-conditioned
medium
from
A2780
cells
during
differentiation.
Effects
on
gene
expression,
membrane
protein
levels,
release
soluble
proteins
response
measured
compared
control
macrophages.
Tumor
cell
conditioning
induced
expression
both
mRNA
level.
Furthermore,
simultaneously
increased
phenotype
markers
CD206
CD80,
checkpoint
LILRB1.
However,
did
not
reduce
phagocytic
capacity,
as
similar
degrees
cell-conditioned
In
vitro
blockade,
suggesting
that
induction
with
does
directly
limit
capacity
for
cells.
conclusion,
these
findings
suggest
CD163+
remain
responsive
highlighting
their
potential
targets
cancer.
Cancer Immunology Immunotherapy,
Год журнала:
2025,
Номер
74(4)
Опубликована: Фев. 25, 2025
Cancer
cells
grow
and
survive
in
the
tumor
microenvironment,
which
is
a
complicated
process.
As
key
part
of
how
colorectal
cancer
(CRC)
progresses,
tumor-associated
macrophages
(TAMs)
exhibit
double
role.
Through
angiogenesis,
this
TAM
can
promote
growth
cancers.
Although
being
able
to
modify
adjust
immune
great
advantage,
these
also
anti-cancer
properties
including
direct
killing
cells,
presenting
antigens,
aiding
T
cell-mediated
responses.
The
delicate
regulatory
mechanisms
between
system
tumors
are
composed
complex
network
pathways
regulated
by
several
factors
hypoxia,
metabolic
reprogramming,
cytokine/chemokine
signaling,
cell
interactions.
Decoding
figuring
out
systems
become
significant
building
targeted
treatment
programs.
Targeting
TAMs
CRC
involves
disrupting
chemokine
signaling
or
adhesion
molecules,
reprogramming
them
an
anti-tumor
phenotype
using
TLR
agonists,
CD40
modulation,
selectively
removing
subsets
that
growth.
Multi-drug
resistance,
absence
accurate
biomarker,
drug
non-specificity
major
problems.
Combining
macrophage-targeted
therapies
with
chemotherapy
immunotherapy
may
revolutionize
treatment.
Macrophage
studies
will
advance
new
technology
multi-omics
methodologies
help
us
understand
build
specific
efficient
treatments.
